ClinicalTrials.gg
RecruitingNCT06544187RESPIREUpdated Mar 27, 2026

Can Imaging be an Alternative to Exercise Testing as a Predictor of Surgical Fitness?

An observational study in Surgical Fitness and Imaging, sponsored by University Hospitals of North Midlands NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by University Hospitals of North Midlands NHS Trust · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
56
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to explore an alternative method for assessing a participant's readiness for surgery, specifically for those undergoing surgery for gastric, oesophageal, or pancreatic cancer. Surgery for these diseases is extremely demanding on the body and surgeons need to be confident that a patient can tolerate the procedure.

Traditionally, participants undergo Cardiopulmonary Exercise Tests (CPET) to determine their fitness for surgery. This involves cycling on an exercise bike with increasing resistance until the resistance is too great to continue cycling at a constant rate. An individual's maximum rate of oxygen consumption (VO2max) and the anaerobic threshold (AT) are calculated during CPET and used by surgeons as a predictor for surgical fitness. CPET tests can be physically demanding for participants and are very resource intensive. Furthermore, some patients may not be able to tolerate exercise tests due to physical constraints.

An alternative method, Magnetic Resonance Spectroscopy (MRS), could be used to measure an individual's fitness prior to surgery. Within this study, MRS will be used to determine the levels of fat within the thigh muscle, which in turn may be able to be used to predict fitness for surgery.

The first phase includes recruiting participants on the surgical pathway. MRS will be performed as an additional examination, typically on the same day as the CPET. Fat levels determined from MRS will be compared with conventional CPET outcomes (VO2max and AT). This analysis aims to determine if MRS derived fat levels correlates with VO2max and AT and, if correlation is high, potentially providing an alternative to CPET for patients who cannot tolerate exercise tests.

The second phase involves recruiting volunteers who will undergo repeated MRS scans to assess the reliability of MRS methods. This process allows us to understand the consistency of MRS derived fat levels over both short and long-term intervals.

The potential benefits of this project include an additional pathway for assessing fitness for surgery or enhancing the presurgical pathway for patients by providing an alternative method for fitness assessment. This study aims to provide evidence that could present an alternative method of assessing a patient's fitness for surgery. The goal is to explore an alternative that may complement or refine current practices in preoperative assessments.

02

Conditions studied

  • Surgical Fitness
  • Imaging
03

In context

Lead sponsor

University Hospitals of North Midlands NHS Trust is the lead sponsor of 28 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Cohort 1: Participants with oesophageal, gastric or pancreatic cancer who are potential candidates for surgical resection (oesophagectomy/gastrectomy/pancreaticoduodenectomy).

Cohort 2: Healthy volunteers who are UHNM staff members ≥ 18 years old, with no known contraindication to MRI. Volunteers will be age and gender matched to the participants in cohort 1.

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for patients (cohort 1)

  • Patients diagnosed oesophageal/gastric or pancreatic cancer.
  • Patients who have or a under consideration for a CPET investigation.
  • Aged ≥ 18.
  • Existing UHNM Patient.
  • Willing and able to give fully .
  • Willing and able to comply with the study procedures.

Inclusion criteria for staff volunteers (cohort 2)

  • Aged ≥ 18 years.
  • Willing and able to give fully informed consent.
  • Willing and able to comply with the study procedures.
  • UHNM member of staff.

Exclusion Criteria:

Exclusion criteria for patients (cohort 1)

  • Patients with to MRI due to safety at 3T.
  • Patients with metalwork within the imaging field of view (e.g., knee replacement).
  • Claustrophobic patients.
  • Patients outside of stated age range to ensure informed consent.
  • Patients not referred for CPET investigations.
  • Patients that are pregnant.
  • Patients that are unable to communicate in English.
  • Patients lacking the capacity and capability to give fully informed consent.
  • Patients participating in any other interventional studies with a contraindication to their participation.
  • Patients for whom the addition of an MRS scan would delay any part of their standard treatment pathway.
  • History of diabetes.

Exclusion criteria for staff volunteers (cohort 2)

  • Volunteers with contraindications to MRI due to safety at 3T.
  • Volunteers with metalwork within the imaging field of view (e.g., knee replacement).
  • Claustrophobic volunteers.
  • Volunteers outside of stated age range to ensure informed consent.
  • Volunteers that are pregnant.
  • Volunteers that are unable to communicate in English.
  • Volunteers lacking the capacity and capability to give fully informed consent.
  • Volunteers participating in any other interventional studies with a contraindication to their participation.
  • Known or suspected medical conditions pertinent to the area being scanned.
  • History of diabetes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
56 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants

    The first phase of the study will involve 56 participants who are potential candidates for oesophagectomy, gastrectomy or pancreaticoduodenectomy procedures following a confirmed cancer diagnosis. Participants who provide their consent will undergo Magnetic Resonance Spectroscopy (MRS) scans of their semitendinosus muscle in the thigh. Participants on this pathway also undergo Cardiopulmonary Exercise Test (CPET) tests, which is a standard procedure. No delay to their normal treatment pathway will be introduced from the addition of the MRS scan, and MR scans can be arranged within two weeks from referral

    Diagnostic Test: MRS scan · Diagnostic Test: CPET

  • Healthy volunteers

    25 healthy volunteers. Their role will be to help us understand the consistency in Intra-Myocellular Liquid (IMCL) composition using Magnetic Resonance Spectroscopy (MRS) techniques. These volunteers will be sourced from the UHNM Trust staff, in accordance with Trust Standard Operating Procedure (SOP): The Safe Scanning of Volunteers in Magnetic Resonance Imagine (MRI). Each volunteer will undergo two MRS scans initially. All three MRS scans will be performed in a single session, with the session lasting about 20 minutes. Additionally, each volunteer will return for a single repeat session of MRS acquisition using the same MRI system and protocol, scheduled at two weeks after the initial scans

    Diagnostic Test: MRS scan · Diagnostic Test: CPET

Interventions

  • Diagnostic testMRS scan

    Magnetic Resonance Spectroscopy scan on the thigh

  • Diagnostic testCPET

    Cardiopulmonary Exercise Test

06

What researchers measure

Primary outcomes

  1. Correlations between levels

    Calculate the correlation between the intramyocellular lipid (IMCL) saturation index and Cardiopulmonary Exercise Test (CPET) derived VO2max and Anaerobic Threshold (AT).

    Time frame: 2 years

Secondary outcomes

  1. Comparisons between participants who did not suffer major morbidity

    Compare the mean Intra-Myocellular Lipid (IMCL) saturation index for patients who suffered major morbidity after oesophagectomy, gastrectomy, or pancreaticoduodenectomy and compare this to the mean IMCL saturation index of those who did not suffer major morbidity.

    Time frame: 2 years

  2. Short and long term repeatability

    Assess the short- and long-term repeatability of Magnetic Resonance Spectroscopy (MRS) of Intra-Myocellular Lipid (IMCL) saturation index measurements in healthy volunteers. .

    Time frame: 2 years

  3. Difference in IMCL composition

    Assess the difference in Intra-Myocellular Lipid (IMCL) composition between patients considered for surgery and age and gender matched volunteers

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Participant data will not be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Sep 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 9, 2024
StartActual
Jan 6, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Dec 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06544187
Lead sponsor
University Hospitals of North Midlands NHS Trust
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Jan 6, 2025
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Aviva Ogbolosingha
Contact
aviva.ogbolosingha@uhnm.nhs.uk
01782 675380

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion